Head-to-Head Comparison of 12 GLP-1 Drugs for Weight Loss: From 4 kg to 23 kg — Which Works Best? | Research

The takeaway

A meta-analysis of 55 trials and 16,269 participants found that triple-agonist retatrutide achieved the greatest weight loss (22.6 kg max), while at one year, triple agonists averaged 24 kg versus 11 kg for dual and 7 kg for single GLP-1 agonists.

24.15 kg at 52 weeks
Average weight loss with triple-agonists (GLP-1/GIP/glucagon) at one year — approaching bariatric surgery-level results

What the researchers found

Across 55 placebo-controlled trials of 12 GLP-1 receptor agonists in 16,269 participants, maximum weight reduction ranged from 4.25 kg (liraglutide) to 22.6 kg (retatrutide). At 52 weeks, the hierarchy was clear: mono-agonists averaged 7.03 kg, dual-agonists 11.07 kg, and tri-agonists 24.15 kg of weight loss.

Onset times varied considerably: orforglipron showed effects fastest (6.4 weeks) while tirzepatide was slowest to plateau (19.5 weeks). Six drugs showed significant dose-response relationships. Age was negatively correlated with weight loss (younger patients lost more), while baseline weight and BMI had no significant impact on outcomes. GI adverse events (nausea, vomiting, diarrhea, constipation) were significantly more common than placebo, with nausea being the most frequent.

Why it matters

This is the most comprehensive head-to-head comparison of GLP-1 weight loss drugs to date, providing the quantitative data clinicians and patients need to make informed treatment decisions. The clear dose-response relationships and the dramatic superiority of multi-receptor agonists (dual and triple) suggest that the next generation of drugs will be substantially more effective — though the trade-off with GI side effects must be carefully managed.

How the study worked

Model-based meta-analysis of placebo-controlled randomized clinical trials identified through systematic review of public databases. Time-course, dose-response, and covariate models characterized efficacy across 12 GLP-1 receptor agonists. Subgroup analyses compared mono-, dual-, and tri-agonists. Meta-analyses compared adverse event incidence and dropout rates across drugs.

What this study cannot tell us

The analysis compares drugs across separate trials rather than head-to-head RCTs, introducing potential confounders from differences in study populations and designs. Some newer drugs (retatrutide, orforglipron) have limited Phase III data. The model-based approach assumes certain mathematical relationships in dose-response and time-course that may not perfectly capture biological reality. Long-term safety and weight maintenance after drug discontinuation are not addressed.

How to read the evidence

This is a model-based meta-analysis of 55 placebo-controlled RCTs — a high level of evidence. The systematic approach, large participant pool, and dose-response modeling strengthen conclusions. However, cross-trial comparisons are inherently less reliable than head-to-head RCTs.

When this study was published

Published in 2025, this is a very current meta-analysis capturing the full spectrum of GLP-1 receptor agonists including the newest triple agonists still in late-stage clinical development.

The bigger picture

This meta-analysis documents the rapid evolution of incretin-based obesity treatment — from first-generation mono-agonists producing modest weight loss to triple agonists approaching bariatric surgery-level results. The trajectory suggests that pharmacological obesity treatment is on the cusp of matching surgical outcomes, potentially making weight loss surgery unnecessary for many patients. The competitive landscape among drug companies is driving rapid innovation in this space.

Questions still open

Will the dramatic weight loss from triple agonists translate to proportionally greater cardiovascular and metabolic benefits, or is there a ceiling effect?
Can the GI side effect burden of more potent multi-agonists be reduced through dosing optimization or combination with anti-nausea agents?
Why does age negatively correlate with weight loss — is this metabolic, behavioral, or pharmacokinetic?

Common questions

What is the difference between single, dual, and triple agonists?

Single (mono) agonists like liraglutide and semaglutide activate only the GLP-1 receptor. Dual agonists like tirzepatide also activate the GIP receptor, boosting weight loss. Triple agonists like retatrutide additionally activate the glucagon receptor, producing the most dramatic weight loss of all. Each additional receptor target appears to amplify the metabolic effects, but may also increase side effects.

Does starting weight affect how much weight you lose on GLP-1 drugs?

Surprisingly, this meta-analysis found that baseline weight and BMI did not significantly affect the amount of weight lost. However, age did matter — younger patients tended to lose more weight. This means GLP-1 drugs appear to be roughly equally effective whether you start at 200 or 300 pounds, which is encouraging for patients across the weight spectrum.

Read the original research

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.

Obesity pillars, 13, 100162

View on PubMed ↗Publisher’s paper ↗

Citation

Guo, Haoyang; Yang, Juan; Huang, Jihan; Xu, Ling; Lv, Yinghua; Wang, Yexuan; Ren, Jiyuan; Feng, Yulin; Zheng, Qingshan; Li, Lujin. (2025). Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.. Obesity pillars, 13, 100162. https://doi.org/10.1016/j.obpill.2025.100162